Merck & Co., Inc. Logo

Merck & Co., Inc.

MRK

(2.2)
Stock Price

98,05 USD

18.44% ROA

29.27% ROE

20.02x PER

Market Cap.

275.077.581.200,00 USD

86.71% DER

2.84% Yield

19.22% NPM

Merck & Co., Inc. Stock Analysis

Merck & Co., Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Merck & Co., Inc. Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

2 Dividend

With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.

3 ROE

ROE in an average range (10.67%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (8.11%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 DER

The stock maintains a fair debt to equity ratio (85%), indicating a reasonable balance between the money it owes and the ownership it possesses.

6 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

7 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (1.632), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

8 PBV

The stock's elevated P/BV ratio (6.26x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

9 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

Merck & Co., Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Merck & Co., Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Merck & Co., Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Merck & Co., Inc. Revenue
Year Revenue Growth
1985 3.547.500.000
1986 4.128.900.000 14.08%
1987 5.061.300.000 18.42%
1988 5.939.500.000 14.79%
1989 6.550.500.000 9.33%
1990 7.671.500.000 14.61%
1991 8.602.700.000 10.82%
1992 9.662.500.000 10.97%
1993 10.498.200.000 7.96%
1994 14.969.800.000 29.87%
1995 16.681.100.000 10.26%
1996 19.828.700.000 15.87%
1997 23.636.900.000 16.11%
1998 26.898.200.000 12.12%
1999 32.714.000.000 17.78%
2000 40.363.200.000 18.95%
2001 47.715.700.000 15.41%
2002 51.790.300.000 7.87%
2003 22.485.900.000 -130.32%
2004 22.938.600.000 1.97%
2005 22.011.900.000 -4.21%
2006 22.636.000.000 2.76%
2007 24.197.700.000 6.45%
2008 23.850.300.000 -1.46%
2009 27.428.300.000 13.04%
2010 45.987.000.000 40.36%
2011 48.047.000.000 4.29%
2012 47.267.000.000 -1.65%
2013 44.033.000.000 -7.34%
2014 42.237.000.000 -4.25%
2015 39.498.000.000 -6.93%
2016 39.807.000.000 0.78%
2017 40.122.000.000 0.79%
2018 42.294.000.000 5.14%
2019 46.840.000.000 9.71%
2020 41.518.000.000 -12.82%
2021 48.704.000.000 14.75%
2022 59.283.000.000 17.84%
2023 63.848.000.000 7.15%
2023 60.115.000.000 -6.21%
2024 64.624.000.000 6.98%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Merck & Co., Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 1.172.800.000 100%
1994 1.230.600.000 4.7%
1995 1.331.400.000 7.57%
1996 1.487.300.000 10.48%
1997 1.683.700.000 11.66%
1998 1.821.100.000 7.54%
1999 2.068.300.000 11.95%
2000 2.343.800.000 11.75%
2001 2.456.400.000 4.58%
2002 2.677.200.000 8.25%
2003 3.178.100.000 15.76%
2004 4.010.200.000 20.75%
2005 3.848.000.000 -4.22%
2006 4.782.900.000 19.55%
2007 4.882.800.000 2.05%
2008 4.805.300.000 -1.61%
2009 5.845.000.000 17.79%
2010 10.991.000.000 46.82%
2011 8.467.000.000 -29.81%
2012 8.168.000.000 -3.66%
2013 7.503.000.000 -8.86%
2014 7.180.000.000 -4.5%
2015 6.704.000.000 -7.1%
2016 7.194.000.000 6.81%
2017 9.982.000.000 27.93%
2018 9.752.000.000 -2.36%
2019 9.872.000.000 1.22%
2020 13.397.000.000 26.31%
2021 12.245.000.000 -9.41%
2022 13.548.000.000 9.62%
2023 13.228.000.000 -2.42%
2023 30.531.000.000 56.67%
2024 11.544.000.000 -164.48%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Merck & Co., Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 8.002.000.000 100%
2019 8.715.000.000 8.18%
2020 7.155.000.000 -21.8%
2021 7.634.000.000 6.27%
2022 7.842.000.000 2.65%
2023 0 0%
2023 8.204.000.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Merck & Co., Inc. EBITDA
Year EBITDA Growth
1985 936.900.000
1986 1.134.100.000 17.39%
1987 1.543.200.000 26.51%
1988 2.067.500.000 25.36%
1989 2.411.300.000 14.26%
1990 2.858.000.000 15.63%
1991 3.316.500.000 13.82%
1992 3.740.800.000 11.34%
1993 4.948.400.000 24.4%
1994 5.052.700.000 2.06%
1995 4.678.600.000 -8%
1996 5.072.900.000 7.77%
1997 5.643.700.000 10.11%
1998 5.266.000.000 -7.17%
1999 7.539.200.000 30.15%
2000 9.628.000.000 21.7%
2001 10.938.500.000 11.98%
2002 11.069.300.000 1.18%
2003 9.439.500.000 -17.27%
2004 7.581.200.000 -24.51%
2005 7.752.500.000 2.21%
2006 5.983.300.000 -29.57%
2007 13.064.400.000 54.2%
2008 6.811.200.000 -91.81%
2009 -5.014.400.000 235.83%
2010 11.406.000.000 143.96%
2011 9.785.000.000 -16.57%
2012 10.795.000.000 9.36%
2013 8.345.000.000 -29.36%
2014 19.208.000.000 56.55%
2015 7.969.000.000 -141.03%
2016 9.017.000.000 11.62%
2017 8.266.000.000 -9.09%
2018 10.250.000.000 19.36%
2019 12.879.000.000 20.41%
2020 9.562.000.000 -34.69%
2021 16.917.000.000 43.48%
2022 23.308.000.000 27.42%
2023 23.992.000.000 2.85%
2023 7.536.000.000 -218.37%
2024 29.332.000.000 74.31%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Merck & Co., Inc. Gross Profit
Year Gross Profit Growth
1985 2.457.600.000
1986 2.984.800.000 17.66%
1987 3.827.000.000 22.01%
1988 4.618.300.000 17.13%
1989 5.221.900.000 11.56%
1990 6.147.400.000 15.06%
1991 6.931.600.000 11.31%
1992 7.887.800.000 12.12%
1993 8.387.100.000 5.95%
1994 9.688.700.000 13.43%
1995 9.892.000.000 2.06%
1996 11.240.400.000 12%
1997 12.683.700.000 11.38%
1998 13.723.600.000 7.58%
1999 16.007.200.000 14.27%
2000 19.197.000.000 16.62%
2001 18.739.200.000 -2.44%
2002 18.736.700.000 -0.01%
2003 18.170.600.000 -3.12%
2004 17.978.800.000 -1.07%
2005 16.862.300.000 -6.62%
2006 16.634.900.000 -1.37%
2007 18.057.000.000 7.88%
2008 18.267.800.000 1.15%
2009 18.409.400.000 0.77%
2010 27.591.000.000 33.28%
2011 31.176.000.000 11.5%
2012 30.821.000.000 -1.15%
2013 27.079.000.000 -13.82%
2014 25.469.000.000 -6.32%
2015 24.564.000.000 -3.68%
2016 25.916.000.000 5.22%
2017 27.347.000.000 5.23%
2018 28.785.000.000 5%
2019 32.728.000.000 12.05%
2020 27.900.000.000 -17.3%
2021 35.078.000.000 20.46%
2022 41.872.000.000 16.23%
2023 46.792.000.000 10.51%
2023 43.989.000.000 -6.37%
2024 47.452.000.000 7.3%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Merck & Co., Inc. Net Profit
Year Net Profit Growth
1985 539.900.000
1986 675.700.000 20.1%
1987 906.400.000 25.45%
1988 1.206.800.000 24.89%
1989 1.495.400.000 19.3%
1990 1.781.200.000 16.05%
1991 2.121.700.000 16.05%
1992 1.984.200.000 -6.93%
1993 2.166.200.000 8.4%
1994 2.997.000.000 27.72%
1995 3.335.200.000 10.14%
1996 3.881.300.000 14.07%
1997 4.614.100.000 15.88%
1998 5.248.200.000 12.08%
1999 5.890.500.000 10.9%
2000 6.821.700.000 13.65%
2001 7.281.800.000 6.32%
2002 7.149.500.000 -1.85%
2003 6.830.900.000 -4.66%
2004 5.813.400.000 -17.5%
2005 4.631.300.000 -25.52%
2006 4.433.800.000 -4.45%
2007 3.275.400.000 -35.37%
2008 7.808.400.000 58.05%
2009 12.901.300.000 39.48%
2010 861.000.000 -1398.41%
2011 6.272.000.000 86.27%
2012 6.661.000.000 5.84%
2013 4.404.000.000 -51.25%
2014 11.920.000.000 63.05%
2015 4.442.000.000 -168.35%
2016 5.691.000.000 21.95%
2017 2.568.000.000 -121.61%
2018 6.220.000.000 58.71%
2019 9.843.000.000 36.81%
2020 7.067.000.000 -39.28%
2021 13.049.000.000 45.84%
2022 14.519.000.000 10.12%
2023 18.980.000.000 23.5%
2023 365.000.000 -5100%
2024 21.820.000.000 98.33%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Merck & Co., Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 0
1986 0 0%
1987 0 0%
1988 1 0%
1989 1 0%
1990 1 0%
1991 1 0%
1992 1 100%
1993 1 0%
1994 1 100%
1995 1 0%
1996 2 0%
1997 2 0%
1998 2 50%
1999 3 0%
2000 3 0%
2001 3 33.33%
2002 3 0%
2003 3 -50%
2004 3 0%
2005 2 0%
2006 2 0%
2007 -1 300%
2008 4 133.33%
2009 4 25%
2010 0 0%
2011 2 100%
2012 2 0%
2013 2 -100%
2014 4 75%
2015 2 -300%
2016 2 50%
2017 1 0%
2018 2 100%
2019 4 33.33%
2020 3 -50%
2021 5 60%
2022 6 0%
2023 7 28.57%
2023 0 0%
2024 9 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Merck & Co., Inc. Free Cashflow
Year Free Cashflow Growth
1989 947.700.000
1990 1.384.800.000 31.56%
1991 1.392.500.000 0.55%
1992 1.437.800.000 3.15%
1993 2.035.800.000 29.37%
1994 3.130.600.000 34.97%
1995 1.938.700.000 -61.48%
1996 4.231.000.000 54.18%
1997 4.867.800.000 13.08%
1998 3.354.900.000 -45.1%
1999 3.570.200.000 6.03%
2000 4.959.500.000 28.01%
2001 6.355.200.000 21.96%
2002 7.159.000.000 11.23%
2003 7.946.500.000 9.91%
2004 7.073.000.000 -12.35%
2005 6.205.800.000 -13.97%
2006 5.785.000.000 -7.27%
2007 5.988.200.000 3.39%
2008 5.273.400.000 -13.55%
2009 1.931.400.000 -173.04%
2010 9.144.000.000 78.88%
2011 10.660.000.000 14.22%
2012 8.068.000.000 -32.13%
2013 10.106.000.000 20.17%
2014 5.543.000.000 -82.32%
2015 11.138.000.000 50.23%
2016 8.762.000.000 -27.12%
2017 4.559.000.000 -92.19%
2018 8.307.000.000 45.12%
2019 9.967.000.000 16.65%
2020 5.569.000.000 -78.97%
2021 9.661.000.000 42.36%
2022 14.707.000.000 34.31%
2023 9.143.000.000 -60.86%
2023 6.815.000.000 -34.16%
2024 4.846.000.000 -40.63%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Merck & Co., Inc. Operating Cashflow
Year Operating Cashflow Growth
1989 1.380.700.000
1990 2.055.600.000 32.83%
1991 2.434.000.000 15.55%
1992 2.504.400.000 2.81%
1993 3.048.500.000 17.85%
1994 4.139.900.000 26.36%
1995 2.944.200.000 -40.61%
1996 5.427.700.000 45.76%
1997 6.316.600.000 14.07%
1998 5.328.300.000 -18.55%
1999 6.130.700.000 13.09%
2000 7.687.300.000 20.25%
2001 9.079.900.000 15.34%
2002 9.528.700.000 4.71%
2003 9.862.400.000 3.38%
2004 8.799.100.000 -12.08%
2005 7.608.500.000 -15.65%
2006 6.765.200.000 -12.47%
2007 6.999.200.000 3.34%
2008 6.571.700.000 -6.51%
2009 3.392.000.000 -93.74%
2010 10.822.000.000 68.66%
2011 12.383.000.000 12.61%
2012 10.022.000.000 -23.56%
2013 11.654.000.000 14%
2014 7.860.000.000 -48.27%
2015 12.421.000.000 36.72%
2016 10.376.000.000 -19.71%
2017 6.447.000.000 -60.94%
2018 10.922.000.000 40.97%
2019 13.440.000.000 18.74%
2020 10.253.000.000 -31.08%
2021 14.109.000.000 27.33%
2022 19.095.000.000 26.11%
2023 13.006.000.000 -46.82%
2023 7.717.000.000 -68.54%
2024 5.637.000.000 -36.9%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Merck & Co., Inc. Capital Expenditure
Year Capital Expenditure Growth
1989 433.000.000
1990 670.800.000 35.45%
1991 1.041.500.000 35.59%
1992 1.066.600.000 2.35%
1993 1.012.700.000 -5.32%
1994 1.009.300.000 -0.34%
1995 1.005.500.000 -0.38%
1996 1.196.700.000 15.98%
1997 1.448.800.000 17.4%
1998 1.973.400.000 26.58%
1999 2.560.500.000 22.93%
2000 2.727.800.000 6.13%
2001 2.724.700.000 -0.11%
2002 2.369.700.000 -14.98%
2003 1.915.900.000 -23.69%
2004 1.726.100.000 -11%
2005 1.402.700.000 -23.06%
2006 980.200.000 -43.1%
2007 1.011.000.000 3.05%
2008 1.298.300.000 22.13%
2009 1.460.600.000 11.11%
2010 1.678.000.000 12.96%
2011 1.723.000.000 2.61%
2012 1.954.000.000 11.82%
2013 1.548.000.000 -26.23%
2014 2.317.000.000 33.19%
2015 1.283.000.000 -80.59%
2016 1.614.000.000 20.51%
2017 1.888.000.000 14.51%
2018 2.615.000.000 27.8%
2019 3.473.000.000 24.7%
2020 4.684.000.000 25.85%
2021 4.448.000.000 -5.31%
2022 4.388.000.000 -1.37%
2023 3.863.000.000 -13.59%
2023 902.000.000 -328.27%
2024 791.000.000 -14.03%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Merck & Co., Inc. Equity
Year Equity Growth
1985 2.634.000.000
1986 2.569.100.000 -2.53%
1987 2.116.700.000 -21.37%
1988 2.855.800.000 25.88%
1989 4.030.500.000 29.15%
1990 4.383.700.000 8.06%
1991 5.510.800.000 20.45%
1992 5.630.000.000 2.12%
1993 11.166.100.000 49.58%
1994 12.347.800.000 9.57%
1995 14.022.000.000 11.94%
1996 14.280.700.000 1.81%
1997 13.797.900.000 -3.5%
1998 16.506.800.000 16.41%
1999 16.702.100.000 1.17%
2000 19.853.400.000 15.87%
2001 20.887.600.000 4.95%
2002 23.128.800.000 9.69%
2003 19.491.600.000 -18.66%
2004 19.695.100.000 1.03%
2005 20.323.800.000 3.09%
2006 19.965.800.000 -1.79%
2007 20.591.400.000 3.04%
2008 21.167.100.000 2.72%
2009 61.492.600.000 65.58%
2010 56.805.000.000 -8.25%
2011 56.943.000.000 0.24%
2012 55.463.000.000 -2.67%
2013 52.326.000.000 -6%
2014 48.791.000.000 -7.25%
2015 44.767.000.000 -8.99%
2016 40.308.000.000 -11.06%
2017 34.569.000.000 -16.6%
2018 26.882.000.000 -28.6%
2019 26.001.000.000 -3.39%
2020 25.404.000.000 -2.35%
2021 38.257.000.000 33.6%
2022 46.058.000.000 16.94%
2023 41.300.000.000 -11.52%
2023 37.635.000.000 -9.74%
2024 43.648.000.000 13.78%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Merck & Co., Inc. Assets
Year Assets Growth
1985 4.902.200.000
1986 5.105.200.000 3.98%
1987 5.680.000.000 10.12%
1988 6.127.500.000 7.3%
1989 6.756.700.000 9.31%
1990 8.029.800.000 15.85%
1991 9.498.500.000 15.46%
1992 11.086.000.000 14.32%
1993 19.927.500.000 44.37%
1994 21.856.600.000 8.83%
1995 23.831.800.000 8.29%
1996 24.293.100.000 1.9%
1997 25.811.900.000 5.88%
1998 31.853.400.000 18.97%
1999 35.634.900.000 10.61%
2000 39.910.400.000 10.71%
2001 44.006.700.000 9.31%
2002 47.561.200.000 7.47%
2003 40.587.500.000 -17.18%
2004 42.572.800.000 4.66%
2005 44.845.800.000 5.07%
2006 44.569.800.000 -0.62%
2007 48.350.700.000 7.82%
2008 47.195.700.000 -2.45%
2009 112.089.700.000 57.89%
2010 105.781.000.000 -5.96%
2011 105.128.000.000 -0.62%
2012 106.132.000.000 0.95%
2013 105.645.000.000 -0.46%
2014 98.335.000.000 -7.43%
2015 101.779.000.000 3.38%
2016 95.377.000.000 -6.71%
2017 87.872.000.000 -8.54%
2018 82.637.000.000 -6.33%
2019 84.397.000.000 2.09%
2020 91.588.000.000 7.85%
2021 105.694.000.000 13.35%
2022 109.160.000.000 3.18%
2023 106.727.000.000 -2.28%
2023 106.675.000.000 -0.05%
2024 112.630.000.000 5.29%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Merck & Co., Inc. Liabilities
Year Liabilities Growth
1985 2.268.200.000
1986 2.536.100.000 10.56%
1987 3.563.300.000 28.83%
1988 3.271.700.000 -8.91%
1989 2.726.200.000 -20.01%
1990 3.646.100.000 25.23%
1991 3.987.700.000 8.57%
1992 5.456.000.000 26.91%
1993 8.761.400.000 37.73%
1994 9.508.800.000 7.86%
1995 9.809.800.000 3.07%
1996 10.012.400.000 2.02%
1997 12.014.000.000 16.66%
1998 15.346.600.000 21.72%
1999 18.932.800.000 18.94%
2000 20.057.000.000 5.61%
2001 23.119.100.000 13.24%
2002 24.432.400.000 5.38%
2003 21.095.900.000 -15.82%
2004 22.877.700.000 7.79%
2005 24.522.000.000 6.71%
2006 24.604.000.000 0.33%
2007 27.759.300.000 11.37%
2008 26.028.600.000 -6.65%
2009 50.597.100.000 48.56%
2010 48.976.000.000 -3.31%
2011 48.185.000.000 -1.64%
2012 50.669.000.000 4.9%
2013 53.319.000.000 4.97%
2014 49.544.000.000 -7.62%
2015 57.012.000.000 13.1%
2016 55.069.000.000 -3.53%
2017 53.303.000.000 -3.31%
2018 55.755.000.000 4.4%
2019 58.396.000.000 4.52%
2020 66.184.000.000 11.77%
2021 67.437.000.000 1.86%
2022 63.102.000.000 -6.87%
2023 65.427.000.000 3.55%
2023 69.040.000.000 5.23%
2024 68.982.000.000 -0.08%

Merck & Co., Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
24.67
Net Income per Share
5.42
Price to Earning Ratio
20.02x
Price To Sales Ratio
4.4x
POCF Ratio
16.48
PFCF Ratio
20.92
Price to Book Ratio
6.31
EV to Sales
4.82
EV Over EBITDA
14.29
EV to Operating CashFlow
18.07
EV to FreeCashFlow
22.93
Earnings Yield
0.05
FreeCashFlow Yield
0.05
Market Cap
275,08 Bil.
Enterprise Value
301,52 Bil.
Graham Number
45.8
Graham NetNet
-17.77

Income Statement Metrics

Net Income per Share
5.42
Income Quality
1.22
ROE
0.34
Return On Assets
0.1
Return On Capital Employed
0.17
Net Income per EBT
0.89
EBT Per Ebit
0.92
Ebit per Revenue
0.24
Effective Tax Rate
0.11

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0.32
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.75
Operating Profit Margin
0.24
Pretax Profit Margin
0.22
Net Profit Margin
0.19

Dividends

Dividend Yield
0.03
Dividend Yield %
2.84
Payout Ratio
0.56
Dividend Per Share
3.08

Operating Metrics

Operating Cashflow per Share
6.59
Free CashFlow per Share
5.19
Capex to Operating CashFlow
0.21
Capex to Revenue
0.06
Capex to Depreciation
0.88
Return on Invested Capital
0.19
Return on Tangible Assets
0.18
Days Sales Outstanding
72.47
Days Payables Outstanding
80.23
Days of Inventory on Hand
147.49
Receivables Turnover
5.04
Payables Turnover
4.55
Inventory Turnover
2.47
Capex per Share
1.4

Balance Sheet

Cash per Share
4,50
Book Value per Share
17,22
Tangible Book Value per Share
2.17
Shareholders Equity per Share
17.2
Interest Debt per Share
15.4
Debt to Equity
0.87
Debt to Assets
0.34
Net Debt to EBITDA
1.25
Current Ratio
1.47
Tangible Asset Value
5,50 Bil.
Net Current Asset Value
-30,78 Bil.
Invested Capital
73511000000
Working Capital
12,15 Bil.
Intangibles to Total Assets
0.34
Average Receivables
12,49 Bil.
Average Payables
3,52 Bil.
Average Inventory
6489500000
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Merck & Co., Inc. Dividends
Year Dividends Growth
1970 1
1971 2 50%
1972 1 -100%
1973 1 0%
1974 1 0%
1975 1 0%
1976 1 0%
1977 1 0%
1978 2 0%
1979 2 0%
1980 2 50%
1981 3 0%
1982 3 0%
1983 3 0%
1984 3 0%
1985 3 33.33%
1986 2 -50%
1987 3 0%
1988 2 -100%
1989 2 0%
1990 2 50%
1991 2 0%
1992 1 -100%
1993 1 0%
1994 1 0%
1995 1 0%
1996 1 0%
1997 2 0%
1998 2 0%
1999 1 0%
2000 1 0%
2001 1 0%
2002 1 0%
2003 4 75%
2004 1 -300%
2005 2 0%
2006 2 0%
2007 2 0%
2008 2 0%
2009 2 0%
2010 2 0%
2011 2 0%
2012 2 0%
2013 2 0%
2014 2 0%
2015 2 0%
2016 2 0%
2017 2 0%
2018 2 0%
2019 2 50%
2020 2 0%
2021 3 0%
2022 3 0%
2023 3 0%
2024 2 0%

Merck & Co., Inc. Profile

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

CEO
Mr. Robert M. Davis J.D.
Employee
70.000
Address
2000 Galloping Hill Road
Kenilworth, 07033

Merck & Co., Inc. Executives & BODs

Merck & Co., Inc. Executives & BODs
# Name Age
1 Dr. Dean Y. Li M.D., Ph.D.
Executive Vice President & President of Merck Research Laboratories
70
2 Ms. Caroline Litchfield
Executive Vice President & Chief Financial Officer
70
3 Mr. Dalton E. Smart III
Senior Vice President of Finance, Principal Accounting Officer & Global Controller
70
4 Mr. Sanat Chattopadhyay
Executive Vice President & President of Merck Manufacturing Division
70
5 Mr. Peter Dannenbaum
Vice President of Investor Relations
70
6 Ms. Cristal N. Downing
Executive Vice President and Chief Communications & Public Affairs Officer
70
7 Ms. Jennifer L. Zachary J.D.
Executive Vice President & General Counsel
70
8 Mr. David Michael Williams
Executive Vice President and Chief Information & Digital Officer
70
9 Mr. Richard R. DeLuca Jr.
Executive Vice President & President of Merck Animal Health
70
10 Mr. Robert M. Davis J.D.
Chairman, President & Chief Executive Officer
70

Merck & Co., Inc. Competitors

AbbVie Inc. Logo
AbbVie Inc.

ABBV

(2.0)
Pfizer Inc. Logo
Pfizer Inc.

PFE

(2.5)
Amgen Inc. Logo
Amgen Inc.

AMGN

(3.2)
Johnson & Johnson Logo
Johnson & Johnson

JNJ

(2.8)